alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Exhibit 32.1

# Written Statement of
the Chief Executive Officer and Chief Financial OfficerPursuant to 18 U.S.C. §1350

Solely
for the purposes of complying with 18 U.S.C. §1350, as adopted pursuant to Section
906 of the Sarbanes-Oxley Act of 2002, we, the undersigned President and Chief Executive
Officer and Vice President Law/Finance and Secretary of Ladish Co., Inc. (the
Company), hereby certify, based on our knowledge, that the Report on Form 10-Q
of the Company for the quarter ended September 30, 2008 (the Report) fully
complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934 and
that information contained in the Report fairly presents, in all material respects, the
financial condition and results of operations of the Company.

/s/ Kerry L. Woody   Kerry L. Woody
 President and Chief Executive Officer

/s/ Wayne E. Larsen  Wayne E. Larsen
Vice President Law/Finance & Secretary

October 31, 2008
Editorial Note on Part 870
Editorial Note: Nomenclature changes to part 870 appear at 73 FR 35341, June 23, 2008.

§ 870.2770 Impedance plethysmograph. ( a ) *Identification.* An impedance plethysmograph is a device used to estimate peripheral blood flow by measuring electrical impedance changes in a region of the body such as the arms and legs.
( b ) *Classification.* Class II (special controls). The device, when it is a body composition analyzer which is not intended to diagnose or treat any medical condition, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 870.9.
[45 FR 7907, Feb. 5, 1980, as amended at 84 FR 71812, Dec. 30, 2019]
If this opinion indicates that it is “FOR PUBLICATION,” it is subject to 

revision until final publication in the Michigan Appeals Reports.

-1-

S T A T E O F M I C H I G A N

C O U R T O F A P P E A L S

TRILLIUM CYBER, INC.,

Plaintiff/Counterdefendant-Appellant,

UNPUBLISHED

April 23, 2020

v No. 345494

Oakland Circuit Court

CANBUSHACK, INC., and ROBERT LEALE, LC No. 2017-161732-CB

Defendants/CounterplaintiffsAppellees.

Before: GADOLA, P.J., and STEPHENS and SHAPIRO, JJ.

SHAPIRO, J. (concurring).

I concur in the result only.

/s/ Douglas B. Shapiro
- All
            - Title
            - Author
            - Subject
            - Date
            - Full-Text

            -                              Explore                            ******                - Educational Resources
              - Archival Collections
              -                                      Themes                                    ******                  - Economic Data
                - Federal Reserve
                - View all 
              - Timelines 
            -                              Browse                            ******                - Titles
              - Authors
              - Subjects
              - Dates 
            -                              About                            ******                - About FRASER
              - FAQ
              - Contact Us
              -                                      FRASER API                                    ******                  - REST API
                - OAI-PMH 
            - Inside FRASER Blog

            - **

Home                 > Browse by Title > Series of Studies on Employment of Women in Various Defense Industries

              																								United States. Women's Bureau.						"Women's Employment in the Making of Steel, 1943 : Women's Bureau Bulletin, No. 192-5" in *Series of Studies on Employment of Women in Various Defense Industries : Women's Bureau Bulletin, No. 192*			(1944).						https://fraser.stlouisfed.org/title/5465/item/539657, accessed on September 25, 2024.	    

        - **FRASER**
        - About
        - FAQ
        - Legal and Privacy
        - FRASER API

          -                              @FedFRASER 
          - ** Contact Us
          -  **  What's New  
          -  **  Inside FRASER
### IN THE UNI TED STAT ES COURT OFAPPEALS FOR THE FIF TH CIRCU IT

No. 10-41178 Summary Calendar

UNITED STATES OF AMERICA, Plaintiff-Appellee

v. JOSE ELIAS SALINAS, Defendant-Appellant

Appeal from the United States District Court for the Eastern District of Texas USDC No. 1:08-CR-164-5
Before BENAVIDES, STEWART, and CLEMENT, Circuit Judges. PER CURIAM: * The attorney appointed to represent Jose Elias Salinas has moved for leave to withdraw and has filed a brief in accordance with Anders v. California , 386 U.S. 738 ( 1967), and United State s v . Flores , 632 F.3d 229 ( 5th Cir. 2011). Salinas has not filed a response. We have reviewed c o u n s e l ’ s b rief and the relevant portio n s o f the record reflected therein. We concur with counsel’s assessment that the appeal presents no nonfrivolous issue for appellate review. Accordingly, counsel’s motion fo r l e ave to withdraw is GRANTED, counsel is excused from further responsibilities herein, and the APPEAL IS DISMISSED. See5 T H C I R
. R. 42.2. U n i te d S ta te s C o u rt o f A p p ea l s F i ft h C i rc u i t 

### F I L E D August 24, 20 11 Lyle W . Cayce Clerk

Purs uant to 5 T H C IR

. R. 47.5 , the cour t has d ete rm inedt hat this op inion sho uld not * be publ ish ed and is not pr ece dent excep t unde r the lim ite d cir cum st ance s se t forth in 5 T H C IR

. R. 47.5 .4. Case: 10-41178 Document: 00511581499 Page: 1 Date Filed: 08/24/2011
Amendment to the Authorized Wholesaler U.S. Sales Agreement

This  Amendment  to  the  Authorized   Apple   Wholesale  U.S.  Sales  Agreement
("Agreement")  amends the  Authorized  Apple  Wholesaler  U.S.  Sales  Agreement
("Agreement")   entered  into  between  Apple  Computer,   Inc.   ("Apple")  and
________________________  ("Wholesaler") in Cupertino,  CA on  _________________
19__.

The parties agree to amend the Agreement as follows;

1.    Add Section 3D to the Agreement as is below:

      "D.  Wholesaler  will purchase  Products only from Apple as covered by the
      terms and conditions herein, unless otherwise authorized by Apple."

2.    Section 3C(9) is added to the Agreement as follows:

      "(9) Wholesaler  will review and use  commercially  reasonable  efforts to
      perform any  remediation  necessary for  Wholesaler to continue to perform
      its obligations under this Agreement after January 1, 2000."

3.    The first sentence of Section 7B(2),  "Wholesaler  understands  that Apple
      does not sell software." is removed.

4.    Section  12E(1) is amended by adding the following  sentence at the end of
      the section:

      "If Apple does not purchase Product  remaining in Wholesaler's  inventory,
      Wholesaler may sell the Product solely to an Authorized  Apple Reseller or
      to an Authorized Apple Wholesaler subject to Apple's approval."

5.    All other terms and conditions of the Agreement shall remain unchanged and
      in full force and effect.  Where there are conflicts between the Agreement
      and this Amendment, this Amendment will prevail.

Thne parties execute this Amendment through their authorized  representatives as
of the dates set forth below.

                Wholesaler                              Apple Computer, Inc.

SIGNATURE:___________________________      SIGNATURE:___________________________
PRINT NAME:__________________________      PRINT NAME:__________________________
TITLE:_______________________________      TITLE:_______________________________
DATE:________________________________      DEPT.:  Bids & Contracts Management
                                           EFFECTIVE DATE:______________________
<TABLE> <S> <C>

<ARTICLE> 5
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                           JAN-3-1999
<PERIOD-END>                               MAR-29-1998
<CASH>                                         359,000
<SECURITIES>                                         0
<RECEIVABLES>                                  469,000
<ALLOWANCES>                                    96,000
<INVENTORY>                                  2,082,000
<CURRENT-ASSETS>                             4,912,000
<PP&E>                                      61,807,000
<DEPRECIATION>                              26,872,000
<TOTAL-ASSETS>                              78,408,000
<CURRENT-LIABILITIES>                       13,677,000
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                       157,000
<OTHER-SE>                                  38,222,000
<TOTAL-LIABILITY-AND-EQUITY>                78,408,000
<SALES>                                     32,322,000
<TOTAL-REVENUES>                            32,407,000
<CGS>                                        9,792,000
<TOTAL-COSTS>                               18,464,000
<OTHER-EXPENSES>                             9,777,000
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                             397,000
<INCOME-PRETAX>                              1,857,000
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                          1,857,000
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 1,857,000
<EPS-PRIMARY>                                      .13
<EPS-DILUTED>                                      .12
        

</TABLE>
Editorial Note on Part 866
Editorial Note: Nomenclature changes to part 866 appear at 73 FR 35341, June 23, 2008.

§ 866.5700 Whole human plasma or serum immunological test system. ( a ) *Identification.* A whole human plasma or serum immunological test system is a device that consists of reagents used to measure by immunochemical techniques the proteins in plasma or serum. Measurements of proteins in plasma or serum aid in the diagnosis of any disease concerned with abnormal levels of plasma or serum proteins, e.g., agammaglobulinemia, allergies, multiple myeloma, rheumatoid vasculitis, or hereditary angioneurotic edema.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 866.9.
[47 FR 50823, Nov. 9, 1982, as amended at 59 FR 63007, Dec. 7, 1994; 66 FR 38793, July 25, 2001]
Editorial Note on Part 862
Editorial Note: Nomenclature changes to part 862 appear at 73 FR 35341, June 23, 2008.

§ 862.1475 Lipoprotein test system. ( a ) *Identification.* A lipoprotein test system is a device intended to measure lipoprotein in serum and plasma. Lipoprotein measurements are used in the diagnosis and treatment of lipid disorders (such as diabetes mellitus), atherosclerosis, and various liver and renal diseases.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 862.9.
[52 FR 16122, May 1, 1987, as amended at 65 FR 2307, Jan. 14, 2000]
**Final Listing of Questionnaire Files for Steam Electric Rulemaking Record**

**Plant ID 08676**  **Removed from Public**  **(Non-CBI) Docket**  **1 Copyright** 

**Flag 2**  **File Name Description**  

### x 08676\08676_Checklist.xls EPA Technical Review Checklist Workbook

08676\08676_Completeness_Checklist.xls EPA Completeness Review Checklist 08676\08676_HardcopyLog.doc EPA log of hardcopy documents submitted x 08676\08676_PartA.xls Plant submitted survey file

08676\Certification Statement_Plant ID_08676.pdf Plant certification statement

1Final reviewed survey responses are located in the Steam Electric Technical Questionnaire Database
. 2 Copyright documents are available from the docket.
Editorial Note on Part 874
Editorial Note: Nomenclature changes to part 874 appear at 73 FR 35341, June 23, 2008.

§ 874.1600 Olfactory test device. ( a ) *Identification.* An olfactory test device is used to determine whether an olfactory loss is present. The device includes one or more odorants that are presented to the patient's nose to subjectively assess the patient's ability to perceive odors.
( b ) *Classification.* Class II (special controls). The special control for these devices is the FDA guidance document entitled “Class II Special Controls Guidance Document: Olfactory Test Device.” For the availability of this guidance document, see § 874.1(e). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 874.9. When indicated for the screening or diagnosis of diseases or conditions other than the loss of olfactory function, the device is not exempt from premarket notification procedures.
[71 FR 32835, June 7, 2006]
Editorial Note on Part 864
Editorial Note: Nomenclature changes to part 864 appear at 73 FR 35341, June 23, 2008.

§ 864.7750 Prothrombin time test. ( a ) *Identification.* A prothrombin time test is a device used as a general screening procedure for the detection of possible clotting factor deficiencies in the extrinsic coagulation pathway, which involves the reaction between coagulation factors III and VII, and to monitor patients receiving coumarin therapy (the administration of one of the coumarin anticoagulants in the treatment of venous thrombosis or pulmonary embolism).
( b ) *Classification.* Class II (performance standards).
[45 FR 60626, Sept. 12, 1980]
# C_2016402EN.01003101.xml

| 31.10.2016 | EN | Official Journal of the European Union | C 402/31 |
| --- | --- | --- | --- |

31.10.2016

EN

Official Journal of the European Union

C 402/31

---

Judgment of the General Court of 15 September 2016 — Cargill v Council

(Case T-117/14) (1)

1

((Dumping - Imports of biodiesel originating in Argentina - Definitive anti-dumping duty - Action for annulment - Direct concern - Individual concern - Admissibility - Article 2(5) of Regulation (EC) No 1225/2009 - Normal value - Production costs))

(2016/C 402/33)

Language of the case: English

Parties

Parties

Applicant: Cargill SACI (Buenos Aires, Argentina) (represented by: J.-F. Bellis, R. Luff and G. Bathory, lawyers)

Applicant:

Defendant: Council of the European Union (represented initially by S. Boelaert and B. Driessen, and subsequently by H. Marcos Fraile, acting as Agents, and by R. Bierwagen and C. Hipp, lawyers)

Defendant:

Interveners in support of the defendant: European Commission (represented by M. França and A. Stobiecka-Kuik, acting as Agents) and European Biodiesel Board (EBB) (Brussels, Belgium) (represented by O. Prost and M.-S. Dibling, lawyers)

Interveners in support of the defendant:

Re:

Re:

Action pursuant to Article 263 TFUE for annulment of Council Implementing Regulation (EU) No 1194/2013 of 19 November 2013 imposing a definitive anti-dumping duty and collecting definitively the provisional duty imposed on imports of biodiesel originating in Argentina and Indonesia (OJ 2013 L 315, p. 2) in so far as it imposes an anti-dumping duty on the applicant.

Operative part of the judgment

Operative part of the judgment

The Court:

| 1. | Annuls Articles 1 and 2 of Council Implementing Regulation (EU) No 1194/2013 of 19 November 2013 imposing a definitive anti-dumping duty and collecting definitively the provisional duty imposed on imports of biodiesel originating in Argentina and Indonesia, in so far as they concern Cargill SACI; |
| --- | --- |

1.

Annuls Articles 1 and 2 of Council Implementing Regulation (EU) No 1194/2013 of 19 November 2013 imposing a definitive anti-dumping duty and collecting definitively the provisional duty imposed on imports of biodiesel originating in Argentina and Indonesia, in so far as they concern Cargill SACI;

| 2. | Orders the Council of the European Union to bear its own costs and to pay the costs incurred by Cargill; |
| --- | --- |

2.

Orders the Council of the European Union to bear its own costs and to pay the costs incurred by Cargill;

| 3. | Orders the European Commission and the European Biodiesel Board (EBB) to bear their own costs. |
| --- | --- |

3.

Orders the European Commission and the European Biodiesel Board (EBB) to bear their own costs.

---

(1)  OJ C 151, 19.5.2014.

1

---
```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 7562 Introduced in House (IH)]

<DOC>

118th CONGRESS
  2d Session
                                H. R. 7562

To amend the Federal Reserve Act to prohibit Federal reserve banks from 
                  paying interest on excess reserves.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                             March 6, 2024

 Mr. Davidson introduced the following bill; which was referred to the 
                    Committee on Financial Services

_______________________________________________________________________

                                 A BILL

 
To amend the Federal Reserve Act to prohibit Federal reserve banks from 
                  paying interest on excess reserves.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Prohibition on IOER Act of 2024''.

SEC. 2. PROHIBITION ON PAYMENT OF EARNINGS ON SURPLUS RESERVES.

    Section 19(b)(12) of the Federal Reserve Act (12 U.S.C. 461(b)(12)) 
is amended--
            (1) in the heading, by inserting ``required reserve'' 
        before ``balances'';
            (2) in subparagraph (A), by inserting after ``Balances'' 
        the following: ``of reserves required to be maintained by a 
        depository institution under paragraph (2) that are'';
            (3) by redesignating subparagraph (C) as subparagraph (D); 
        and
            (4) by inserting after subparagraph (B) the following:
                    ``(C) Prohibition on other earnings.--A Federal 
                reserve bank may not pay earnings on balances 
                maintained at a Federal reserve bank by or on behalf of 
                a depository institution except as provided under this 
                paragraph.''.
                                 <all>
```
Exhibit 10.36


 


Exhibit A


 


NOTE: Information in this document marked
with an "[*]" has been omitted and filed separately with the
Commission. Confidential treatment has been requested with respect to the
omitted portions.


 


Ciphergen
Discount Schedule


 


Annual
Units


 


1-20 instruments


 


21 to 30 instruments


 


35 instruments* and above                                                (Non-Cancelable order)


 


In order to
qualify for [*], A non-Cancelable order of [*] units will be placed o


   All Units must be released by Ciphergen
within one Calendar year


   (All
Units shipped in one Calendar year will count towards the total number of units
§ 876.3500 Penile implant surgical accessories. ( a ) *Identification.* Penile implant surgical accessories are manual devices designed to be used for surgical procedures associated with the implantation of a penile inflatable implant or penile rigidity implant. This generic type of device includes the cylinder sizer, cylinder insertion tool and needle, device placement tool, connector assembly tool, incision closing tool, corporeal dilator, tubing passer, measurement tool or tape, tubing plug, blunt needle, and hemostat shod tubing.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 876.9.
[84 FR 14869, Apr. 12, 2019]
Editorial Note on Part 874
Editorial Note: Nomenclature changes to part 874 appear at 73 FR 35341, June 23, 2008.

§ 874.3320 Group hearing aid or group auditory trainer. ( a ) *Identification.* A group hearing aid or group auditory trainer is a hearing aid that is intended for use in communicating simultaneously with one or more listeners having hearing impairment. The device is used with an associated transmitter microphone. It may be either monaural or binaural, and it provides coupling to the ear through either earphones or earmolds. The generic type of device includes three types of applications: hardwire systems, inductance loop systems, and wireless systems.
( b ) *Classification.* Class II (special controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 874.9.
[51 FR 40389, Nov. 6, 1986, as amended at 84 FR 71813, Dec. 30, 2019]
NOTE: This disposition is nonprecedential. 

United States Court of Appeals for the Federal Circuit 

 2009-1065 

HIGHMARK, INC., 

Plaintiff-Appellee, 

v. 

ALLCARE HEALTH MANAGEMENT SYSTEMS, INC., 

 Defendant-Appellant. 

Cynthia E. Kernick, Reed Smith LLP, of Pittsburgh, Pennsylvania, argued for 

plaintiff-appellee. With her on the brief were James C. Martin, Kevin S. Katona, and 

Richard T. Ting. 

Steven G. Hill, Hill, Kertscher & Wharton, LLP, of Atlanta, Georgia, argued for 

defendant-appellant. With him on the brief was Joseph F. Cleveland, Jr., Brackett & 

Ellis, P.C., of Fort Worth, Texas. 

Appealed from: United States District Court for the Northern District of Texas 

Judge Terry Means 
NOTE: This disposition is nonprecedential. 

United States Court of Appeals for the Federal Circuit 

2009-1065 

HIGHMARK, INC., 

Plaintiff-Appellee, 

v. 

ALLCARE HEALTH MANAGEMENT SYSTEMS, INC., 

Defendant-Appellant. 

 Judgment

ON APPEAL from the United States District Court for the Northern District of Texas 

in CASE NO(S). 4:03-CV-1384 

This CAUSE having been heard and considered, it is 

ORDERED and ADJUDGED: 

Per Curiam (MICHEL, Chief Judge, NEWMAN, and DYK, Circuit Judges). 

 AFFIRMED. See Fed. Cir. R. 36. 

ENTERED BY ORDER OF THE COURT 

 

DATED July 13, 2009 /s/ Jan Horbaly 

Jan Horbaly, Clerk
# C_2015381EN.01003202.xml

| 16.11.2015 | EN | Official Journal of the European Union | C 381/32 |
| --- | --- | --- | --- |

16.11.2015

EN

Official Journal of the European Union

C 381/32

---

Order of the General Court of 16 September 2015 — Bionorica v Commission

(Case T-619/14) (1)

1

((Action for failure to act - Consumer protection - Health claims made on foods - Regulation (EC) No 1924/2006 - Botanical substances - Time-limit for bringing an action - No legal interest in bringing proceedings - Act not amenable to review - Inadmissibility))

(2015/C 381/36)

Language of the case: German

Parties

Parties

Applicant: Bionorica SE (Neumark, Germany) (represented by: M. Weidner, N. Hußmann and T. Guttau, lawyers)

Applicant:

Defendant: European Commission (represented by: M. Wilderspin and S. Grünheid, acting as Agents)

Defendant:

Re:

Re:

Application seeking a declaration that the Commission failed to act in that it unlawfully refrained from ordering the European Food Safety Authority (EFSA) to evaluate the health claims relating to botanical substances as a condition prior to the adoption of the definitive list of authorised health claims in accordance with Article 13(3) of Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and health claims made on foods (OJ 2006 L 404, p. 9).

Operative part of the order

Operative part of the order

| 1. | The action is dismissed as inadmissible. |
| --- | --- |

1.

The action is dismissed as inadmissible.

| 2. | Bionorica SE shall pay the costs. |
| --- | --- |

2.

Bionorica SE shall pay the costs.

---

(1)  OJ C 409, 17.11.2014.

1

---